selected scholarly activity
-
books
-
chapters
- Pneumonia, Community-Acquired. 1763-1766. 2012
- Streptococcus Pneumoniae Infections. 1820-1823. 2012
- Infections of the lower respiratory tract. 574-588. 2010
- Treatment of Community-Acquired Respiratory Tract Infections. 227-243. 2003
- Improved safety profile of newer fluoroquinolones. Milestones in Drug Therapy. 73-85. 2003
- Interactions Among Subinhibitory Antibiotics, Aerobic Gram-negative Rods, and Human Polymorphonuclear Neutrophils. 133-143. 1989
- A Model for in Vitro Testing of Drug Effects on Neutrophil Function. 173-185. 1987
- Interactions between human Polymorphonuclear Neutrophils and Ampicillin treated Escherichia coli. 166-178. 1985
- The Effects of Antibacterial, Antiviral, and Antifungal Drugs on the Phagocytic, Microbicidal, and Chemotactic Functions of the Human Polymorphonuclear Leukocyte. 40-55. 1982
-
conferences
- Treatment of nosocomial pneumonia. International Journal of Antimicrobial Agents. S31-S31. 2013
- RESISTANCE PHENOTYPES OF STREPTOCOCCUS PNEUMONIAE AND CLINICAL OUTCOME OF RESPIRATORY TRACT INFECTIONS TREATED WITH GEMIFLOXACIN. Chest. 371S-371S. 2005
- Update on community-acquired pneumonia. Postgraduate Medicine. 35-46. 2005
- Macrolides and management of community-acquired pneumonia: A review of international guidelines. European Respiratory Review. 85-87. 2004
- An overview of the efficacy of gemifloxacin for the treatment of community-acquired pneumonia (CAP). Chest. 847S-848S. 2004
- Future Trends in Antimicrobial Chemotherapy: Expert Opinion on the 43rdICAAC. Journal of Chemotherapy. 419-436. 2004
- Safety and Efficacy of Gemifloxacin Compared to High Dose Amoxicillin/Clavulanate for the Treatment of Community-Acquired Pneumonia (CAP) of Suspected Pneumococcal Origin. Chest. 847S-847S. 2004
- Safety and Tolerability of Gemifloxacin: A Review of Clinical Trial Data. Chest. 848S-848S. 2004
- The Efficacy of 5-Day Gemifloxacin Once Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis (AECB). Chest. 838S-838S. 2004
- Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES). Diagnostic Microbiology and Infectious Disease. 65-67. 2002
- Activity of moxifloxacin against Streptococcus pneumoniae using a murine lung-infection model. Journal of Antimicrobial Chemotherapy. 38-38. 2001
- Efficacy of once-daily gemifloxacin for 5 days compared with twice-daily clarithromycin for 7 days in the treatment of AECB. Journal of Antimicrobial Chemotherapy. 46-46. 2001
- Efficacy of oral gemifloxacin (7-14 days) compared with intravenous ceftriaxone followed by oral cefuroxime (each given for 1-7 days, +/- a macrolide) in the treatment of CAP. Journal of Antimicrobial Chemotherapy. 46-46. 2001
- Gemifloxacin long-term outcomes in bronchitis exacerbations (GLOBE) study - An assessment of health outcome benefits in aecb patients following 5 days' gemifloxacin (GEMI) therapy. Journal of Antimicrobial Chemotherapy. 44-44. 2001
- Transfer of fluoroquinolone (FQ) resistance through recombination. Journal of Antimicrobial Chemotherapy. 35-35. 2001
- First International Moxifloxacin Symposium - Berlin, 1999 - Introduction to the symposium. FIRST INTERNATIONAL MOXIFLOXACIN SYMPOSIUM - BERLIN, 1999. 1-3. 2000
- Introduction: Evolving needs in respiratory tract infections. Clinical Microbiology and Infection (CMI). S1-S8. 1998
- Intravenous to oral antimicrobial stepdown therapy at the Henderson Hospital, Hamilton, Ontario. Canadian Journal of Infectious Diseases and Medical Microbiology. 1995
- A Prospective Open‐Label Multicentre Trial on the Use of 1 G, Once Daily Ceftriaxone in Lower Respiratory Tract Infections. Canadian Journal of Infectious Diseases and Medical Microbiology. 3c-8c. 1994
- Antimicrobial treatment of community acquired pneumonia in adults: A conference report. Canadian Journal of Infectious Diseases and Medical Microbiology. 1994
- Hospital Acquired Pneumonia: Issues in Therapy. Canadian Journal of Infectious Diseases and Medical Microbiology. 15c-19c. 1994
- Workshop 8 Influenza in Canada. American Journal of Medicine. 68-69. 1987
-
journal articles
- Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. Open Forum Infectious Diseases. 9:ofac043. 2022
- Consensus (Convergence of Opinion on Recommendations and Evidence [CORE]) Versus Systematic (Grading of Recommendations Assessment, Development, and Evaluation [GRADE]) Approach to Development of Guidelines for Community-acquired Pneumonia. Clinical Infectious Diseases. 73:e1476-e1477. 2021
- How low can we go in community-acquired pneumonia therapy?. The Lancet. 397:1160-1161. 2021
- Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs. 81:233-256. 2021
- Aspiration Pneumonia. New England Journal of Medicine. 380:e40-e40. 2019
- Aspiration Pneumonia Reply. New England Journal of Medicine. 380. 2019
- Aspiration Pneumonia. New England Journal of Medicine. 380:651-663. 2019
- The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. Expert Review of Respiratory Medicine. 13:139-152. 2019
- Overuse of Antibiotics in Treatment of Community-Acquired Pneumonia Requiring Hospitalization. Infectious Diseases in Clinical Practice. 25:55-56. 2017
- Something New for Community-Acquired Pneumonia?. Clinical Infectious Diseases. 63:1681-1682. 2016
- Community-acquired pneumonia: An overview. Postgraduate Medicine. 127:607-615. 2015
- Empirical Therapy of Community-Acquired Pneumonia. Journal of the American Medical Association (JAMA). 314:396-396. 2015
- Community-Acquired Pneumonia. New England Journal of Medicine. 372:292-294. 2015
- Community-Acquired Pneumonia. New England Journal of Medicine. 372:293-294. 2015
- Guidelines and Quality Measures. Infectious Disease Clinics of North America. 27:71-86. 2013
- Adjunctive Therapy in Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine. 33:311-318. 2012
- Methicillin-Resistant Staphylococcus aureus and Community-Acquired Pneumonia: An Evolving Relationship. Clinical Infectious Diseases. 54:1134-1136. 2012
- Community acquired pneumonia. The BMJ. 341:c2916-c2916. 2010
- Prospective randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia. Thorax. 65:93-94. 2010
- Doripenem: A New Carbapenem in the Treatment of Nosocomial Infection. Clinical Infectious Diseases. 49:S1-S3. 2009
- Severe Community‐Acquired Pneumonia (CAP) and the Infectious Diseases Society of America/American Thoracic Society CAP Guidelines Prediction Rule: Validated or Not. Clinical Infectious Diseases. 48:386-388. 2009
- Spectrum of Microbial Etiology of Community‐Acquired Pneumonia in Hospitalized Patients: Implications for Selection of the Population for Enrollment in Clinical Trials. Clinical Infectious Diseases. 47:S189-S192. 2008
- Guideline Tyranny: A Response to the Article by Baum and Kaltsas. Clinical Infectious Diseases. 47:1117-1118. 2008
- Treatment of Community‐Acquired Pneumonia Down Under versus the United States: Is It Really That Different?. Clinical Infectious Diseases. 46:1522-1524. 2008
- Duration of Treatment for Ventilator-Associated Pneumonia. Infectious Diseases in Clinical Practice. 16:139-141. 2008
- HAP/VAP: Simpler May Be Cetter. Canadian Journal of Infectious Diseases and Medical Microbiology. 19:11-11. 2008
- Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study authors' response. Journal of Antimicrobial Chemotherapy. 60:903-903. 2007
- Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. Journal of Antimicrobial Chemotherapy. 60:112-120. 2007
- Reply to Collins et al. and to Singh. Clinical Infectious Diseases. 45:134-135. 2007
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases. 44:S27-S72. 2007
- Short-Course Therapy of Gemifloxacin Effective Against Pneumococcal Pneumonia in Mice. Journal of Chemotherapy. 18:634-640. 2006
- Medication options for the treatment of CAP.. American Family Physician. 74:1479. 2006
- Cutaneous Adverse Events and Gemifloxacin: Observations from the Clinical Trial Program. Journal of Chemotherapy. 18:447-447. 2006
- Adverse Cutaneous Reactions and Drugs: A Focus on Antimicrobials. Journal of Chemotherapy. 18:127-139. 2006
- Cutaneous Adverse Events and Gemifloxacin: Observations from the Clinical Trial Program. Journal of Chemotherapy. 18:3-11. 2006
- Erratum: Cutaneous adverse events and gemifloxacin: Observations from the clinical trial program (Journal of Chemotherapy (2006) 18,1)). Journal of Chemotherapy. 18:447. 2006
- CARDIO-PULMONARY MEDICAL HISTORY AND THE EFFECT ON CLINICAL OUTCOME OF COMMUNITY-ACQUIRED PNEUMONIA INFECTIONS TREATED WITH GEMIFLOXACIN. Chest. 128:372S-372S. 2005
- Five-Day Telithromycin Once Daily Is as Effective as 10-Day Clarithromycin Twice Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis and Is Associated With Reduced Health-Care Resource Utilization. Chest. 128:1980-1988. 2005
- PATIENT RISK FACTORS IN COMMUNITY-ACQUIRED PNEUMONIA INFECTIONS OUTCOME FOLLOWING TREATMENT WITH GEMIFLOXACIN. Chest. 128:372S-372S. 2005
- THE EFFECT OF DISEASE SEVERITY ON CLINICAL OUTCOME WITH ACUTE EXACERBATION OF CHRONIC BRONCHITIS PATIENTS TREATED WITH GEMIFLOXACIN. Chest. 128:371S-371S. 2005
- Etiologies of Acute Respiratory Tract Infections. Clinical Infectious Diseases. 41:503-506. 2005
- Pneumococcal Serotypes in the Elderly. Clinical Infectious Diseases. 41:488-489. 2005
- High prevalence of macrolide resistance: not in every country! [Comment on: Halpern et al. J Antimicrob Chemother 2005; 55: 748–57]. Journal of Antimicrobial Chemotherapy. 56:433-434. 2005
- Meta-analysis of bacterial resistance to macrolides—providing generalizable results: authors' response. Journal of Antimicrobial Chemotherapy. 56:434-435. 2005
- Meta-analysis of bacterial resistance to macrolides. Journal of Antimicrobial Chemotherapy. 55:748-757. 2005
- Antimicrobial Resistance and Treatment of Community-Acquired Pneumonia. Clinics in Chest Medicine. 26:57-64. 2005
- Decisions about Treating Community-Acquired Pneumonia. ACP journal club. 142:215-215. 2005
- Update of IDSA Guidelines for the Management of Community Acquired Pneumonia (CAP). Japanese Journal of Chemotherapy. 53:23-58. 2005
- Epidemiology and etiology of community-acquired pneumonia. Infectious Disease Clinics of North America. 18:761-776. 2004
- Intravenous (IV) azithromycin (AZM)/ceftriaxone followed by PO AZM versus IV lefofloxacin (LEV) followed by PO LEV in treatment of hospitalized patients with community-acquired pneumonia. Minerva Pneumologica. 43:183-188. 2004
- Legionnaires Disease and the Updated IDSA Guidelines for Community‐Acquired Pneumonia. Clinical Infectious Diseases. 39:1734-1737. 2004
- Reply to Yu et al.. Clinical Infectious Diseases. 39:1737-1738. 2004
- Short-course Gemifloxacin Therapy is Effective Against Streptococcus pneumoniae in a Murine Model of Pneumonia. Chest. 126:847S-847S. 2004
- Novel Murine Model of Pneumococcal Pneumonia: Use of Temperature as a Measure of Disease Severity To Compare the Efficacies of Moxifloxacin and Levofloxacin. Antimicrobial Agents and Chemotherapy. 48:3343-3348. 2004
- Streptococcus pneumoniae: Drug Resistance and Optimal Therapeutic Approaches. Today's Therapeutic Trends. 22:121-145. 2004
- A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. International Journal of Antimicrobial Agents. 23:421-429. 2004
- Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia. Chest. 125:1888-1901. 2004
- Respiratory Fluoroquinolones: Differences in the Details. Clinical Infectious Diseases. 38:1331-1332. 2004
- Comparative Efficacies and Tolerabilities of Intravenous Azithromycin Plus Ceftriaxone and Intravenous Levofloxacin with Step-Down Oral Therapy for Hospitalized Patients with Moderate to Severe Community-Acquired Pneumonia. Treatments in Respiratory Medicine. 3:329-336. 2004
- Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults. Clinical Infectious Diseases. 37:1405-1433. 2003
- Editorial Commentary: Short‐Course Treatment of Community‐Acquired Pneumonia. Clinical Infectious Diseases. 37:761-763. 2003
- Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respiratory Medicine. 97:242-249. 2003
- Editorial Commentary: What is Optimal Antimicrobial Therapy for Bacteremic Pneumococcal Pneumonia?. Clinical Infectious Diseases. 36:396-398. 2003
- Canadian Guidelines for the Management of Acute Exacerbations of Chronic Bronchitis. Canadian Respiratory Journal. 10:3B-32B. 2003
- Canadian Guidelines for the Management of Acute Exacerbations of Chronic Bronchitis: Executive Summary. Canadian Respiratory Journal. 10:248-258. 2003
- Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: A randomized, open-label, multicenter study of clinical efficacy and tolerability. Clinical Therapeutics. 24:1915-1936. 2002
- Acute Bacterial Sinusitis in Adults: Management in the Primary Care Setting. Journal of Otolaryngology - Head and Neck Surgery. 31:S02-S02. 2002
- The Battle against Emerging Antibiotic Resistance: Should Fluoroquinolones Be Used to Treat Children?. Clinical Infectious Diseases. 35:721-727. 2002
- Fluoroquinolones for the treatment of outpatient community-acquired pneumonia. Diagnostic Microbiology and Infectious Disease. 44:69-76. 2002
- Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease. 44:93-100. 2002
- Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia. Diagnostic Microbiology and Infectious Disease. 44:127-128. 2002
- The potency/efficacy of the fluoroquinolones in community-acquired pneumonia. Formulary. 37:27-31. 2002
- A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clinical Therapeutics. 24:639-652. 2002
- An updated safety profile of moxifloxacin.. Journal of Chemotherapy. 14 Suppl 2:29-34. 2002
- Safety of Fluoroquinolones: An Update. Canadian Journal of Infectious Diseases and Medical Microbiology. 13:54-61. 2002
- The appropriate use of the fluoroquinolones: Factors affecting quinolone use versus other agents: Uses and indications. Formulary. 37:36-39. 2002
- Un Aggiornato Profilo di Sicurezza della Moxifloxacina. Journal of Chemotherapy. 14:13-19. 2002
- Interspecies Recombination Contributes Minimally to Fluoroquinolone Resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy. 45:2631-2634. 2001
- Introduction: Clinical relevance of antimicrobial resistance☆. Seminars in Respiratory Infections. 16:153-154. 2001
- Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. Journal of Antimicrobial Chemotherapy. 48:67-74. 2001
- Guidelines for the Management of Adults with Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine. 163:1730-1754. 2001
- Antimicrobial Safety and Tolerability: Differences and Dilemmas. Clinical Infectious Diseases. 32:S72-S79. 2001
- Relationship of penicillin resistance to mortality in pneumococcal pneumonia. Current Infectious Disease Reports. 3:9-12. 2001
- Efficacy of Gemifloxacin in Acute Exacerbations of Chronic Bronchitis: a Randomised, Double-Blind Comparison with Trovafloxacin. Journal of Chemotherapy. 13:288-298. 2001
- Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae : Contributions of Type II Topoisomerase Mutations and Efflux to Levels of Resistance. Antimicrobial Agents and Chemotherapy. 44:3049-3054. 2000
- Canadian Guidelines for the Initial Management of Community-Acquired Pneumonia: An Evidence-Based Update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clinical Infectious Diseases. 31:383-421. 2000
- Guidelines for Community-Acquired Pneumonia: A Tale of 2 Countries. Clinical Infectious Diseases. 31:422-425. 2000
- Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases. 31:347-382. 2000
- Progress in the management of urinary tract infections: discussion. Journal of Antimicrobial Chemotherapy. 46:63-65. 2000
- Gemifloxacin: survival of the fittest. Journal of Antimicrobial Chemotherapy. 46:33-37. 2000
- Gemifloxacin. Drugs. 59:1148-1148. 2000
- Endotracheal Aspiration in the Diagnosis of Ventilator-Associated Pneumonia. Chest. 117:195S-197S. 2000
- Comparative In Vitro Activities of Ciprofloxacin, Gemifloxacin, Grepafloxacin, Moxifloxacin, Ofloxacin, Sparfloxacin, Trovafloxacin, and Other Antimicrobial Agents against Bloodstream Isolates of Gram-Positive Cocci. Antimicrobial Agents and Chemotherapy. 44:802-805. 2000
- Gemifloxacin versus Amoxicillin/Clavulanate in the Treatment of Acute Exacerbations of Chronic Bronchitis. Journal of Chemotherapy. 12:314-325. 2000
- Summary of Canadian Guidelines for the Initial Management of Community-Acquired Pneumonia: An Evidence-Based Update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Canadian Respiratory Journal. 7:371-382. 2000
- Summary of Canadian Guidelines for the Initial Management of Community‐Acquired Pneumonia: An Evidence‐Based Update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Canadian Journal of Infectious Diseases and Medical Microbiology. 11:237-248. 2000
- Treatment of community-acquired pneumonia requiring admission to a hospital ward. Current Infectious Disease Reports. 1:455-457. 1999
- ANTIBIOTIC THERAPY FOR COMMUNITY-ACQUIRED PNEUMONIA. Clinics in Chest Medicine. 20:589-598. 1999
- Two Nursing Home Outbreaks of Respiratory Infection with Legionella sainthelensi. Journal of The American Geriatrics Society. 47:547-552. 1999
- Advances in antimicrobial therapy of community-acquired pneumonia. Current Opinion in Infectious Diseases. 12:137-143. 1999
- Advances in antimicrobial therapy of community-acquired pneumonia. Enfermedades Infecciosas y Microbiologia. 19:202-210. 1999
- Antibiotic and Oral Contraceptive Drug Interactions: Is There a Need for Concern?. Canadian Journal of Infectious Diseases and Medical Microbiology. 10:429-433. 1999
- Comparative Tolerability of the Newer Fluoroquinolone Antibacterials. Drug Safety. 21:407-421. 1999
- Issues and controversies in respiratory medicine. Canadian Respiratory Journal. 6. 1999
- [The role of trovafloxacin in the treatment of nosocomial pneumonia].. Medicina. 59 Suppl 1:39-46. 1999
- New treatment options for pneumonia. Infections in Medicine. 15:34-45. 1998
- PANEL DISCUSSION. Infectious Diseases in Clinical Practice. 7:S217-s220. 1998
- PREFACE. Infectious Disease Clinics of North America. 12:xiii-xiv. 1998
- Community‐Acquired Pneumonia in Adults: Guidelines for Management. Clinical Infectious Diseases. 26:811-838. 1998
- Nosocomial Pneumonia Guidelines. Chest. 113:188S-193S. 1998
- Addition information concerning the comparison of imipenem and meropenem [1] (multiple letters). Canadian Journal of Infectious Diseases and Medical Microbiology. 9:322-326. 1998
- An Integrated Approach to Antimicrobial Stewardship in the Hospital Setting. Canadian Journal of Infectious Diseases and Medical Microbiology. 9:7c-16c. 1998
- Antimicrobial Therapy in the Patient Hospitalized with Pneumonia. Sepsis. 1:189-197. 1998
- Classification, Diagnosis and Treatment of Sinusitis: Evidence‐Based Clinical Practice Guidelines. Canadian Journal of Infectious Diseases and Medical Microbiology. 9:3b-24b. 1998
- Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects. Canadian Journal of Infectious Diseases and Medical Microbiology. 9:215-228. 1998
- Microbiology of Hospital-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine. 18:111-120. 1997
- Sequential antibiotic therapy. Netherlands Journal of Medicine. 50:93-96. 1997
- Decision Analysis Modelling of Costs and Outcomes following Cefepime Monotherapy in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology. 8:19-27. 1997
- Piperacillin/tazobactam. Canadian Journal of Infectious Diseases and Medical Microbiology. 8:79-84. 1997
- Itraconazole: An oral systemic antifungal triazole. Canadian Journal of Infectious Diseases and Medical Microbiology. 7:366-369. 1996
- Management of diabetic foot infection: A position paper. Canadian Journal of Infectious Diseases and Medical Microbiology. 7. 1996
- Quinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Patients: Effect of Augmented Gram-Positive Activity on Infectious Morbidity. ACP journal club. 125:183-183. 1996
- Antimicrobial approaches to therapy for pneumonia. Current Opinion in Pulmonary Medicine. 2:218-227. 1996
- Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995.. American Journal of Respiratory and Critical Care Medicine. 153:1711-1725. 1996
- Community-Acquired Pneumonia. New England Journal of Medicine. 334:861-863. 1996
- A Multidisciplinary Hospital‐based Antimicrobial Use Program: Impact on Hospital Pharmacy Expenditures and Drug Use. Canadian Journal of Infectious Diseases and Medical Microbiology. 7:104-109. 1996
- Lower respiratory tract infections — An overall perspective. American Journal of Medicine. 99:1S-2S. 1995
- Community-Acquired Pneumonia. Chest. 108:35S-42S. 1995
- DETERMINING RISK OF SURGICAL-SITE INFECTIONS - RESPONSE. CANADIAN MEDICAL ASSOCIATION JOURNAL. 152:1382-1382. 1995
- Respiratory Infections: Diagnosis and Management By James E. Pennington. 3rd ed. New York: Raven Press, 1994. 881 pp., illustrated. $99. Clinical Infectious Diseases. 20:733-734. 1995
- Antimicrobial Activity of Ceftriaxone Compared with Cefotaxime in the Presence of Serum Albumin. Canadian Journal of Infectious Diseases and Medical Microbiology. 6:21-27. 1995
- Intravenous to Oral Antimicrobial Stepdown Therapy at the Henderson Hospital, Hamilton, Ontario. Canadian Journal of Infectious Diseases and Medical Microbiology. 6:23a-24a. 1995
- Sequential Antibiotic Therapy: Effective Cost Management and Patient Care. Canadian Journal of Infectious Diseases and Medical Microbiology. 6:306-315. 1995
- METHODOLOGY IN CLINICAL-TRIALS OF PROPHYLAXIS AND TREATMENT OF INFECTIONS IN CANCER-PATIENTS. Bailliere's Clinical Infectious Diseases. 1:455-468. 1994
- Antimicrobial prophylaxis in surgery. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 151:925-931. 1994
- Antibiotics for pneumonia therapy. Medical Clinics of North America. 78:997-1014. 1994
- Cefotetan: a second-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 151:537-542. 1994
- Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 150:669-676. 1994
- Antimicrobial activity of ceftriaxone versus cefotaxime: negative effect of serum albumin binding of ceftriaxone. Journal of Antimicrobial Chemotherapy. 33:1239-1243. 1994
- Pneumonia: A Focus on Treatment. Canadian Respiratory Journal. 1:85-86. 1994
- Response to “Treatment Guidelines for Nosocomial Pneumonia: Agreeing to Disagree”. Canadian Journal of Infectious Diseases and Medical Microbiology. 5:56-57. 1994
- Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group.. British Journal of Surgery. 61-66. 1994
- Medical Section pf the American Lung Association: Guidelines for the Initial Management of Adults with Community-acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy. American Journal of Respiratory and Critical Care Medicine. 148:1418-1426. 1993
- Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group.. American Surgeon. 59:598-605. 1993
- In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci. Diagnostic Microbiology and Infectious Disease. 17:85-91. 1993
- A Prospective Randomized Trial of Imipenem‐Cilastatin Versus Clindamycin/Tobramycin in the Treatmentof Intra‐Abdominal and Pelvic Infections. Canadian Journal of Infectious Diseases and Medical Microbiology. 4:279-287. 1993
- Antimicrobial Treatment of Community Acquired Pneumonia in Adults: A Conference Report. Canadian Journal of Infectious Diseases and Medical Microbiology. 4:25-28. 1993
- Initial Antimicrobial Treatment of Hospital Acquired Pneumonia in Adults: A Conference Report. Canadian Journal of Infectious Diseases and Medical Microbiology. 4:317-321. 1993
- The Renaissance of the Macrolides: New and Changing Roles in Infectious Diseases. Canadian Journal of Infectious Diseases and Medical Microbiology. 4:1-4. 1993
- Effect of acidified enteral feedings on gastric colonization in the critically ill patient. Critical Care Medicine. 20:1388-1394. 1992
- Gastric Colonization by Gram-Negative Bacilli and Nosocomial Pneumonia in the Intensive Care Unit Patient. Chest. 101:187-193. 1992
- Reduction in Clinical Response to Empiric Antimicrobial Therapy of Febrile Granulocytopenic Patients Receiving TMP/SMX Infection Prophylaxis. Canadian Journal of Infectious Diseases and Medical Microbiology. 3:235-239. 1992
- Mechanisms of interaction among subinhibitory concentrations of antibiotics, human polymorphonuclear neutrophils, and gram-negative bacilli. Antimicrobial Agents and Chemotherapy. 35:1291-1297. 1991
- Chemotactic inhibitors in sera of patients with neoplastic disease.. Clinical and Investigative Medicine. 14:131-141. 1991
- Role of quinolones in surgical prophylaxis. European Journal of Clinical Microbiology and Infectious Diseases. 10:368-377. 1991
- Pneumococcal Endometritis with Peritonitis: Case Report and Review of the Literature. Canadian Journal of Infectious Diseases and Medical Microbiology. 2:161-164. 1991
- Synergistic killing of Gram-negative bacilli by cefotaxime, its desacetyl metabolite and human polymorphonuclear neutrophils. Journal of Antimicrobial Chemotherapy. 27:817-828. 1991
- The in-vitro activity of temafloxacin, against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy. 28:15-24. 1991
- Ceftizoxime: a third-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 142:1209-1212. 1990
- Infections in the Compromised Host. Journal of International Medical Research. 18:177-190. 1990
- Once-Daily Therapy with Ceftriaxone Compared with Daily Multiple-Dose Therapy with Cefotaxime for Serious Bacterial Infections: A Randomized, Double-Blind Study. Journal of Infectious Diseases. 160:433-441. 1989
- RIGHTING 2 WRONGS - REPLY. CANADIAN MEDICAL ASSOCIATION JOURNAL. 139:826-826. 1988
- Treatment of parasitic infections: Canadian versus US recommendations. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 139:849-851. 1988
- Imipenem: a new carbapenem. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 139:505-506. 1988
- Norfloxacin: a new quinolone. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 139:305-307. 1988
- Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections. Antimicrobial Agents and Chemotherapy. 32:1231-1236. 1988
- A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia. Journal of Antimicrobial Chemotherapy. 20:95-107. 1987
- A multicenter comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients. JAMA Internal Medicine. 145:1083-1088. 1985
- Management of the febrile neutropenic patient.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 128:915-917. 1983
- A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia. Journal of Antimicrobial Chemotherapy. 12:9-20. 1983
- Effects of Antimicrobial and Antineoplastic Drugs on the Phagocytic and Microbicidal Function of the Polymorphonuclear Leukocyte. Clinical Infectious Diseases. 4:683-697. 1982
- A preliminary report on the use of ceftizoxime vs. clindamycin/tobramycin for the therapy of intra-abdominal and pelvic infections. Journal of Antimicrobial Chemotherapy. 10:191-192. 1982
- The Chemoprophylaxis of Infection: A Brief Review of Recent Studies. Medical Clinics of North America. 62:1083-1098. 1978
- Immunology of Cartilage in Septic Arthritis. Clinical Orthopaedics and Related Research. 108:84-89. 1975